Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SSTR5 | P35346 | 18/20 | 0.70 |
| ▸ | SSTR1 | P30872 | 1/20 | 0.70 |
| ▸ | HRH1 | P35367 | 1/20 | 0.70 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.63 |
| ▸ | HPGDS | O60760 | 1/20 | 0.58 |
| ▸ | UTS2R | Q9UKP6 | 1/20 | 0.53 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2961628 | 0.89 | SSTR5 (0.76) | SSTR5SSTR1HRH1KCNH2 | |
| SCHEMBL2953744 | 0.88 | SSTR5 (0.82) | SSTR5SSTR1HRH1KCNH2 | |
| SCHEMBL2951398 | 0.87 | SSTR5 (0.78) | SSTR5SSTR1HRH1KCNH2 | |
| SCHEMBL2961781 | 0.86 | SSTR5 (0.73) | SSTR5SSTR1HRH1KCNH2 | |
| SCHEMBL2964634 | 0.85 | SSTR5 (0.74) | SSTR5SSTR1HRH1KCNH2UTS2R | |
| SCHEMBL2952035 | 0.85 | SSTR5 (0.74) | SSTR5SSTR1HRH1KCNH2UTS2R | |
| SCHEMBL2956258 | 0.85 | SSTR5 (0.68) | SSTR5SSTR1HRH1KCNH2 | |
| SCHEMBL2955318 | 0.85 | SSTR5 (0.78) | SSTR5SSTR1HRH1KCNH2 | |
| SCHEMBL2958079 | 0.84 | SSTR5 (0.77) | SSTR5SSTR1HRH1KCNH2 | |
| SCHEMBL2957609 | 0.83 | SSTR5 (0.74) | SSTR5SSTR1HRH1KCNH2UTS2R |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7772253-B2 | Amide derivatives as somatostatin receptor 5 antagonists | HOFFMAN-LA ROCHE INC. (US) | 2010-08-10 | — | — | US | disclosed |
| EP-1893603-B1 | PIPERIDIN-4-YL-AMIDE DERIVATIVES AND THEIR USE AS SST RECEPTOR SUBTYPE 5 ANTAGONISTS | HOFFMANN LA ROCHE (CH) | 2009-10-14 | — | — | EP | disclosed |
| EP-1893603-A1 | PIPERIDIN-4-YL-AMIDE DERIVATIVES AND THEIR USE AS SST RECEPTOR SUBTYPE 5 ANTAGONISTS | F. Hoffmann-La Roche AG (CH) | 2008-03-05 | — | — | EP | disclosed |
| WO-2006128803-A1 | PIPERIDIN-4-YL-AMIDE DERIVATIVES AND THEIR USE AS SST RECEPTOR SUBTYPE 5 ANTAGONISTS | F. HOFFMANN-LA ROCHE AG (CH) | 2006-12-07 | — | — | WO | disclosed |
| US-20060276508-A1 | Amide derivatives as somatostatin receptor 5 antagonists | F. HOFFMANN-LA ROCHE AG (CH) | 2006-12-07 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060276508-A1 | Amide derivatives as somatostatin receptor 5 antagonists | SSTR5, SSTR3, SSTR1 | SSTR5 1/4885SSTR1 3/4885HRH1 212/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.